Tempus AI Stock Pulls Back Amid Surge Fueled by Merck and Moderna Results

Tempus AI's stock is experiencing a significant pullback on Monday, having surged by approximately 20% over the last week. The recent surge in value was driven by momentum from Phase 3 INTerpath-001 results from Merck & Co. and Moderna Inc., which put a spotlight on Tempus AI's $1.5 billion deal with Personalis Inc.

Moderna uses Personalis' sequencing platform to analyze tumor tissue and identify specific neoantigens needed to manufacture individualized doses. This partnership has been a key factor in the recent surge in Tempus AI's stock price.

In other news, Tempus AI received FDA 510(k) clearance for ECG-PH, an AI product intended to detect signs of pulmonary hypertension from a standard ECG. This clearance adds pulmonary hypertension to the company's FDA-cleared AI products alongside atrial fibrillation and low ejection fraction.